Skip to main content
Premium Trial:

Request an Annual Quote

Epoch Licenses MGB, Eclipse Technologies to Celera Diagnostics

NEW YORK, Feb. 11 (GenomeWeb News) - Epoch Biosciences of Bothell, Wash., today announced a licensing agreement with Celera Diagnostics.


Epoch will license its MGB and Eclipse Dark Quencher technologies into Celera Diagnostics' products for selected infectious diseases, the company said in a statement.


The license allows Celera Diagnostics to manufacture, sell and distribute TaqMan probes that utilize Epoch's minor groove binder and quencher in selected products. Under the license agreement, Epoch will receive license fees and royalties on sales of such licensed products to end users. Additional terms of the agreement were not disclosed.


Celera Diagnostics is a joint venture between the Celera Genomics and Applied Biosystems of Applera.


The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.